CTIS2023-505522-34-00进行中（未招募）1 期
1305-0034
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participantsCTIS2023-508905-26-00Bayer AG40
进行中（未招募）
1 期
A study in healthy men to test whether itraconazole influences the amount of BI 1584862 in the bloodHealthy volunteer trialMedDRA version: 21.0Level: LLTClassification code: 10053349Term: Pharmacokinetic study Class: 10022891CTIS2023-503542-31-00Boehringer Ingelheim International GmbH14
进行中（未招募）
1 期
A study in healthy men to test how BI 764198 is processed in the bodyHealthyMedDRA version: 21.0Level: LLTClassification code: 10053349Term: Pharmacokinetic study Class: 10022891CTIS2022-502327-22-00Boehringer Ingelheim International GmbH16
进行中（未招募）
1 期
A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapyMetastatic pancreatic ductal adenocarcinoma (mPDAC)MedDRA version: 21.0Level: LLTClassification code: 10033599Term: Pancreatic adenocarcinoma metastatic Class: 10029104CTIS2023-508998-85-00Boehringer Ingelheim International GmbH68
招募中
1 期
A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple dosesInflammatory Gastrointestinal DiseaseMedDRA version: 20.0Level: HLGTClassification code: 10017969Term: Gastrointestinal inflammatory conditions Class: 10017947CTIS2023-507882-24-00Ferring Pharmaceuticals A/S48